Advertisement

Loading...

Curaleaf Holdings, Inc.

CURA.TOTSX
Healthcare
Drug Manufacturers - Specialty & Generic
$3.11
$0.11(3.67%)
Canadian Market opens in 14h 55m

Curaleaf Holdings, Inc. Fundamental Analysis

Curaleaf Holdings, Inc. (CURA.TO) shows weak financial fundamentals with a PE ratio of -6.79, profit margin of -19.01%, and ROE of -29.97%. The company generates $1.3B in annual revenue with weak year-over-year growth of -6.78%.

Key Strengths

PEG Ratio-1.56
Current Ratio1.52

Areas of Concern

ROE-29.97%
Operating Margin1.41%
Cash Position4.22%
We analyze CURA.TO's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -36.9/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-36.9/100

We analyze CURA.TO's fundamental strength across five key dimensions:

Efficiency Score

Weak

CURA.TO struggles to generate sufficient returns from assets.

ROA > 10%
-8.59%

Valuation Score

Excellent

CURA.TO trades at attractive valuation levels.

PE < 25
-6.79
PEG Ratio < 2
-1.56

Growth Score

Moderate

CURA.TO shows steady but slowing expansion.

Revenue Growth > 5%
-6.78%
EPS Growth > 10%
27.50%

Financial Health Score

Moderate

CURA.TO shows balanced financial health with some risks.

Debt/Equity < 1
1.37
Current Ratio > 1
1.52

Profitability Score

Weak

CURA.TO struggles to sustain strong margins.

ROE > 15%
-2996.52%
Net Margin ≥ 15%
-19.01%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is CURA.TO Expensive or Cheap?

P/E Ratio

CURA.TO trades at -6.79 times earnings. This suggests potential undervaluation.

-6.79

PEG Ratio

When adjusting for growth, CURA.TO's PEG of -1.56 indicates potential undervaluation.

-1.56

Price to Book

The market values Curaleaf Holdings, Inc. at 2.19 times its book value. This may indicate undervaluation.

2.19

EV/EBITDA

Enterprise value stands at 3.36 times EBITDA. This is generally considered low.

3.36

How Well Does CURA.TO Make Money?

Net Profit Margin

For every $100 in sales, Curaleaf Holdings, Inc. keeps $-19.01 as profit after all expenses.

-19.01%

Operating Margin

Core operations generate 1.41 in profit for every $100 in revenue, before interest and taxes.

1.41%

ROE

Management delivers $-29.97 in profit for every $100 of shareholder equity.

-29.97%

ROA

Curaleaf Holdings, Inc. generates $-8.59 in profit for every $100 in assets, demonstrating efficient asset deployment.

-8.59%

Following the Money - Real Cash Generation

Operating Cash Flow

Curaleaf Holdings, Inc. produces operating cash flow of $138.99M, showing steady but balanced cash generation.

$138.99M

Free Cash Flow

Curaleaf Holdings, Inc. produces free cash flow of $74.64M, offering steady but limited capital for shareholder returns and expansion.

$74.64M

FCF Per Share

Each share generates $0.10 in free cash annually.

$0.10

FCF Yield

CURA.TO converts 4.37% of its market value into free cash.

4.37%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-6.79

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-1.56

vs 25 benchmark

P/B Ratio

Price to book value ratio

2.19

vs 25 benchmark

P/S Ratio

Price to sales ratio

1.30

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

1.37

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.52

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.30

vs 25 benchmark

ROA

Return on assets percentage

-0.09

vs 25 benchmark

ROCE

Return on capital employed

0.007

vs 25 benchmark

How CURA.TO Stacks Against Its Sector Peers

MetricCURA.TO ValueSector AveragePerformance
P/E Ratio-6.7928.31 Better (Cheaper)
ROE-29.97%699.00% Weak
Net Margin-19.01%-131318.00% (disorted) Weak
Debt/Equity1.370.34 Weak (High Leverage)
Current Ratio1.522775.16 Neutral
ROA-8.59%-14513.00% (disorted) Weak

CURA.TO outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Curaleaf Holdings, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

253.20%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

-105.90%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

365.09%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ